{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-041332","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2023-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.120743+00:00","generated_at":"2026-06-14T19:54:16.827188+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bluejay Diagnostics updates Symphony IL-6 regulatory strategy, expands trial to sepsis patients","bullets":["Trial widened from severe COVID-19 only to all hospitalized sepsis patients to speed enrollment while maintaining H1 2024 submission timeline.","Company to submit FDA pre-submission application for revised study design in Q2 2023.","New indication for risk stratification of hospitalized sepsis patients aligns with recent FDA feedback."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-041332","json":"https://secwatch.observer/filing/0001213900-23-041332.json","markdown":"https://secwatch.observer/filing/0001213900-23-041332.md","text":"https://secwatch.observer/filing/0001213900-23-041332.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023041332/0001213900-23-041332-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023041332/ea178902-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T19:54:16.827188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}